<DOC>
	<DOCNO>NCT00104650</DOCNO>
	<brief_summary>The purpose trial determine effectiveness AMG 162 reduce urinary N-telopeptide advance cancer subject bone metastasis .</brief_summary>
	<brief_title>Study AMG 162 Subjects With Advanced Cancer Currently Being Treated With Intravenous ( IV ) Bisphosphonates</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Patients least 18 year age histologically confirm solid tumor carcinoma ( except lung ) multiple myeloma Radiographic evidence 1 bone lesion lytic lesion myeloma Currently receive IV bisphosphonates Urinary NTelopeptide ( uNTx ) great 50 nM BCE/mM creatinine Eastern Cooperative Oncology Group ( ECOG ) 0 , 1 2 More 2 prior skeletal related event ( SRE ) Known brain metastasis Prior history current evidence osteonecrosis/osteomyelitis jaw Active dental jaw condition require oral surgery Nonhealed dental/oral surgery Prior administration AMG 162 Evidence impending fracture weight bear bone Pregnancy breastfeed . Subjects must surgically sterile , postmenopausal , must agree use effective contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bone Metastases</keyword>
	<keyword>AMG 162</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Solid Tumor Carcinomas</keyword>
	<keyword>Advanced</keyword>
</DOC>